“…and, 6) HSPC-derived macrophages and microglia can deliver lacking protein/enzyme to the disease cells in the injured tissues ( Tan et al, 2019 ). Clinical trials using gene-modified autologous CD34 + HSPCs are being undertaken for genetic diseases such as X-SCID, ADA-SCID, Wiskott-Aldrich syndrome, metachromatic leukodystrophy, X-linked cerebral adrenoleukodystrophy, and mucopolysaccharidosis type I ( Gentner et al, 2021 ; Mamcarz et al, 2019 ; De Ravin et al, 2016 ; Kohn et al, 2021 ; Magnani et al, 2022 ; Ma et al, 2021 ; Ferrua and Aiuti, 2017 ; Morris et al, 2017 ; Biffi et al, 2013 ; Eichler et al, 2017b ; Fumagalli et al, 2022 ). Currently, our lab is conducting a phase 1/2 clinical trial for cystinosis ( ClinicalTrials.gov Identifier: NCT03897361), a multisystemic lysosomal storage disorder, characterized by accumulation of cystine in all tissues and due to mutations or deletions in CTNS gene, encoding a lysosomal cystine transporter ( Cherqui, 2021 ).…”